Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

OTCPK:SHEZ.F Stock Report

Market Cap: US$2.1b

Shenzhen Hepalink Pharmaceutical Group Past Earnings Performance

Past criteria checks 0/6

Shenzhen Hepalink Pharmaceutical Group's earnings have been declining at an average annual rate of -42%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 5.2% per year.

Key information

-41.99%

Earnings growth rate

-44.50%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate5.23%
Return on equity-2.14%
Net Margin-4.36%
Next Earnings Update31 Oct 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shenzhen Hepalink Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:SHEZ.F Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 245,570-243818168
31 Mar 245,518-695878191
31 Dec 235,446-783977182
30 Sep 235,8272181,028238
30 Jun 236,1143401,094268
31 Mar 236,5505591,073258
01 Jan 237,1597271,025252
30 Sep 227,1294321,043279
30 Jun 227,010414987242
31 Mar 227,008332966224
01 Jan 226,365241923221
30 Sep 216,421777834200
30 Jun 215,786781819183
31 Mar 215,198912801160
31 Dec 205,3321,024832160
30 Sep 205,0281,097820106
30 Jun 205,1551,094823125
31 Mar 205,004808815127
31 Dec 194,6251,059762149
30 Sep 194,622812749182
30 Jun 194,736894733135
31 Mar 194,8791,030699165
31 Dec 184,815591682187
30 Sep 184,307565683143
30 Jun 183,905437615163
31 Mar 183,347278574155
31 Dec 172,84319754394
30 Sep 172,48617645168
30 Jun 172,21814045541
31 Mar 172,0451894370
31 Dec 162,2613974420
30 Sep 162,3184664480
30 Jun 162,2795664360
31 Mar 162,2235904270
31 Dec 152,2925803820
30 Sep 152,1415323140
30 Jun 152,2515032990
31 Mar 152,3874533530
31 Dec 141,9593383110
30 Sep 141,7182503000
30 Jun 141,4771772930
31 Mar 141,3752491970
31 Dec 131,5133172050

Quality Earnings: SHEZ.F is currently unprofitable.

Growing Profit Margin: SHEZ.F is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: SHEZ.F is unprofitable, and losses have increased over the past 5 years at a rate of 42% per year.

Accelerating Growth: Unable to compare SHEZ.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SHEZ.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).

Return on Equity

High ROE: SHEZ.F has a negative Return on Equity (-2.14%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/11 15:09
End of Day Share Price 2024/07/15 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ziyi ChenGoldman Sachs
Yinglan ShuHaitong International Research Limited
Laurence TamMorgan Stanley